{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:33:21Z","timestamp":1783085601726,"version":"3.54.6"},"reference-count":28,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To describe the results of the Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES) outcome measures of cognitive, emotional, and physical development following long-term treatment with sertraline (for up to 3 years) in children and adolescents aged 6\u201316 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>SPRITES was a long-term, multicenter, open-label, prospective observational study designed to compare physical and psychological development in pediatric patients exposed to sertraline (with or without psychotherapy) or psychotherapy alone in usual care settings. Data were summarized descriptively, and outcomes were evaluated using a marginal structural model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Between April 2012 and September 2020, 941 patients across 44 U.S. sites participated in the study. At baseline, 695 participants were exposed to sertraline (physician prescribed) with or without psychotherapy, and 245 participants were exposed to psychotherapy alone. Of these, 432 participants (46.0%) completed the full 3-year study follow-up. No significant changes across time were found in standardized height, BRIEF (Behavior Rating Inventory of Executive Function), Trails B, and Tanner stage based on cumulative sertraline exposure or exposure since the last visit. Change in mean standardized weight across time was positively associated with both cumulative sertraline exposure (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.02) and exposure since the last visit (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.029). The mean changes from baseline across time in standardized weight were standard deviations of 0.02, 0.03, 0.16, and 0.17 at months 3, 6, 30, and 36, respectively. However, this finding was not observed in the mean change across time in standardized body mass index, which was not statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Results are consistent with normal development. Although a statistically significant finding for standardized weight was observed in comparative analyses, the magnitude of the change is small and observed at higher doses of sertraline only. No other significant differences were observed between the \u201csertraline\u201d group and the \u201cno pharmacological therapy\u201d group on other primary outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov identifier:<\/jats:title>\n                    <jats:p>NCT01302080.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2022.0048","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T11:06:57Z","timestamp":1676632017000},"page":"2-13","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES)"],"prefix":"10.1177","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-7563","authenticated-orcid":false,"given":"Francesca","family":"Kolitsopoulos","sequence":"first","affiliation":[{"name":"Worldwide Research and Development, Pfizer, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ramaker","sequence":"additional","affiliation":[{"name":"Global Product Development, Pfizer, Collegeville, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott N.","family":"Compton","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Broderick","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Orazem","sequence":"additional","affiliation":[{"name":"Global Product Development, Pfizer, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihang","family":"Bao","sequence":"additional","affiliation":[{"name":"Global Product Development, Pfizer, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Lokhnygina","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Marschall","sequence":"additional","affiliation":[{"name":"Viatris Germany, Frankfurt, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-6236","authenticated-orcid":false,"given":"Phillip","family":"Chappell","sequence":"additional","affiliation":[{"name":"Global Product Development, Pfizer, Groton, Connecticut, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/108705470400700404"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e318145ae1c"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000246070.23695.06"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000220851.94392.30"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2010.09.011"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1037\/0012-1649.26.2.322"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0717"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1076\/chin.6.3.235.3152"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-2832"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2020.0170"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.2432"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0015"},{"key":"e_1_3_5_14_1","unstructured":"Mitrushina M Boone K Razani J. Handbook of Normative Data for Neuropsychological Assessment. Oxford University Press: New York; 2006."},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2004.14.412"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117742659"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01537962"},{"key":"e_1_3_5_18_1","unstructured":"Pratt LA Brody DJ Gu Q. Antidepressant Use Among Persons Aged 12 and Over: United States 2011\u20132014. NCHS Data Brief No. 283. National Center for Health Statistics: Hyattsville MD; 2017."},{"key":"e_1_3_5_19_1","unstructured":"Prozac (fluoxetine) Prescribing Information. Eli Lilly and Company. PROZAC (fda.gov); 1987. Revised October 2021."},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-6177(03)00042-8"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00011"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/008124638901900102"},{"key":"e_1_3_5_23_1","unstructured":"Strauss E Sherman EM Spreen O. A Compendium of Neuropsychological Tests: Administration Norms and Commentary. New York: Oxford University Press 2006."},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3016.2001.00317.x"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-6177(03)00039-8"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.8.1033"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804633"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16m10884"},{"key":"e_1_3_5_29_1","unstructured":"Zoloft (sertraline) Prescribing Information. Pfizer Inc. label (fda.gov); 1991. Revised September 2021."}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2022.0048","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2022.0048","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2022.0048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:56:31Z","timestamp":1777388191000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2022.0048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1089\/cap.2022.0048"],"URL":"https:\/\/doi.org\/10.1089\/cap.2022.0048","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}